Postmarketing retrospective studies of the rituximab biosimilar (CT-P10, Truxima) demonstrated comparable safety and efficacy for treatment of diffuse large B-cell lymphoma (DLBCL).
Celltrion Healthcare reported positive findings from a European Union real-world safety and efficacy study comparing the company’s rituximab biosimilar (CT-P10, Truxima) with the reference product (Rituxan) in patients with diffuse large B-cell lymphoma (DLBCL), the most common subtype of non-Hodgkin lymphoma (NHL). Results were reported at the European Hematology Association 2021 Virtual Congress.
Celltrion also released real-world data demonstrating comparable safety and effectiveness of CT-P10 rapid infusion.
CT-P10 treatment data were collected during a 30-month observation period. Primary end points included overall survival (OS) and progression-free survival (PFS), and secondary end points included safety profile and CT-P10 treatment pathways.
At the 30-month point, OS was 74% (95% CI, 69.2%-79.1%) and PFS was 67% (95% CI, 61.3%-72.1%) among patients (N = 382) undergoing first-line treatment with CT-P10.
Among enrollees, a complete response (CR) was observed in 82% (n = 312); partial response (PR), 12% (n = 46); no response or stable disease 4% (n = 16); and progressive disease, 2% (n = 8).
CT-P10 tolerability also was reported to be comparable to the reference product. The investigators said 90% (n = 351) of patients reported 1 or more adverse events (AEs), 65% (n = 253) experienced a grade 3 or higher event, and 28% of AEs were reported as “definitely, probably, or possibly related to CT-P10.”
“This is the first multicountry retrospective postapproval study to investigate the effectiveness and safety of CT-P10 treatment in patients with DLBCL in a real-world setting across Europe,” said Mark Bishton, MD, consultant hematologist and a clinical associate professor at the University of Nottingham, School of Medicine, England.
The European Medicines Agency approved CT-P10 for treatment of rheumatoid arthritis and certain blood cancers, including NHL, in 2017. DLBCL accounts for an estimated 30% to 40% of NHL incidence.
“The response rates, survival rates and overall safety profile for CT-P10 appear consistent with those reported for reference rituximab, which could support the use of CT-P10 in combination with chemotherapy as a therapeutic option for DLBCL,” authors of the study wrote.
Discussing the second study, the investigators said rapid infusion of CT-P10 was generally well tolerated, with 10% (n = 20; 95% CI, 6%-15%) of patients experiencing infusion-related reactions (IRRs).
“We are encouraged by the results of the study, as CT-P10 has demonstrated a similar IRR rate to reference rituximab,” said HoUng Kim, PhD, head of the Medical and Marketing Division of Celltrion.
The investigators said most IRRs were grade 1/2 (96%), and the most common of these were fatigue (35%), nausea (30%), and vomiting (15%). Patients achieving CRs and PRs over 6 months of observation were 74% and 22%, respectively.
“The recommended protocol for rituximab infusion in Europe is a slow initial infusion rate with a gradual upward titration. Rapid infusion is often used in subsequent infusions for patients who had no serious complications related to the first infusion,” Kim said.
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
Alvotech’s Stelara Biosimilar, Selarsdi, Receives FDA Approval
April 16th 2024Alvotech’s Selarsdi (ustekinumab-aekn), a biosimilar referencing Stelara (ustekinumab), gained FDA approval, making it the second ustekinumab biosimilar and second for the company to be given the green light for the American market.
Biosimilars Rheumatology Roundup for February 2024—Podcast Edition
March 3rd 2024On this episode of Not So Different, The Center for Biosimilars® revisited all the major rheumatology biosimilar news from February 2024, including the FDA approval of the 10th adalimumab biosimilar, the promise for an oral delivery system for ustekinumab, and the impact of adalimumab products on COVID-19 antibodies.
BioRationality: Removing the Misconceptions Surrounding Interchangeability
April 15th 2024Sarfaraz K. Niazi, PhD, outlines the current state of interchangeable biosimilars in the US and policy changes needed to clear up misconceptions surrounding the meaning behind interchangeability designations.
Global Biosimilar Market Projected to Reach $1.3 Trillion by 2032
April 11th 2024The global biosimilar market is projected to surge from $25.1 billion in 2022 to approximately $1.3 trillion by 2032, with a compound annual growth rate of 17.6%, driven mainly by the increasing prevalence of cancer and the cost-effectiveness of biosimilars, as outlined in a report by Towards Healthcare.